Clinical Trial Update: Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a genetically targeted therapy to prevent symptomatic atrial fibrillation in patients with heart failure; study completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Heart Failure

Snippet

Sponsor: ARCA Biopharma, Inc. | Conditions: Current or Recent History of Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2022-09-15